EUCTR2005-001895-11-IT进行中（未招募）不适用
A 96 Week Phase IIIB Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir ATV/RTV with Lopinavir/ritonavir LPV/RTV , Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 infected treatment naive subjects. - Castle
BRISTOL-M.SQUIBB0 个研究点目标入组 1,200 人开始时间: 2006年7月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Antiretroviral-na ve HIV-1 infected subjects with no contraindication to study medications. Subjects must have a confirmed plasma HIV-1 RNA level 61619;2000 c/mL and an absolute CD4 count 61619; 50 cells/mm3.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Woman who are pregnant or breast feeding; Suspected primary acute HIV infection; Any antiretroviral therapy within 30 days prior to screening; Prior antiviral therapy / 1 week; Presence of cardiomiopathy or any significant cardiovascular disease; Screening laboratory values measured as follows calculated creatinine clearance 60 mL/min; total serum lipase / 1.4 times the upper limit of normal; liver enzymes AST,ALT / 5 times the upper limit of normal; total serum bilirubin / 1.5 times the upper limit of normal.
研究者
相似试验
进行中（未招募）
不适用
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavirwith Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabinein HIV-1 Infected Treatment Naive Subjects.Revised Protocol 01: incorporates amendment 03.Pharmacogenetics Blood Sample Amendment 01, version 1.0, dated 21-Sep-05; andMetabolic Pharmacogenetics Substudy Amendment 02, version 1.0, dated 21-Sep-05EUCTR2005-001895-11-ATBristol-Myers Squibb International Corporation1,200
进行中（未招募）
1 期
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment Naive Subjects. Revised Protocol 04 Incorporating changes from Amendment 03, 04, 05, 06 (Version 1.0, Date 03-Apr-2007), and Administrative Letter dated 31-Oct-2006. Pharmacogenetics Blood Sample Amendment 01, version 1.0, dated 21-Sep-05; and Metabolic Pharmacogenetics Substudy Amendment 02, version 1.0, dated 21-Sep-05HIV-1 Infected Treatment Naive SubjectsEUCTR2005-001895-11-GBBristol-Myers Squibb International Corporation1,200
进行中（未招募）
1 期
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavirwith Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabinein HIV-1 Infected Treatment Naive Subjects.Revised Protocol 01: Incorporates changes from Amendment 03.Pharmacogenetics Blood Sample Amendment 01, version 1.0, dated 21-Sep-05; andMetabolic Pharmacogenetics Substudy Amendment 02, version 1.0, dated 21-Sep-05HIV-1 Infected Treatment Naive SubjectsEUCTR2005-001895-11-BEBristol-Myers Squibb International Corporation1,200
进行中（未招募）
不适用
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavirwith Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabinein HIV-1 Infected Treatment Naive Subjects.Revised Protocol 05 Incorporating changes from Amendments 03, 04, 05, 06, 07 (Version 1.0, Date 05-Oct-2007), and Administrative Letter 03. Pharmacogenetics Blood Sample Amendment 01, version 1.0, dated 21-Sep-05; and Metabolic Pharmacogenetics Substudy Amendment 02, version 1.0, dated 21-Sep-05.HIV-1 Infected Treatment Naive SubjectsEUCTR2005-001895-11-DEBristol-Myers Squibb International Corporation1,200
进行中（未招募）
1 期
A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavirwith Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabinein HIV-1 Infected Treatment Naive Subjects.Revised Protocol 01: Incorporates changes from Amendment 03.Pharmacogenetics Blood Sample Amendment 01, version 1.0, dated 21-Sep-05; andMetabolic Pharmacogenetics Substudy Amendment 02, version 1.0, dated 21-Sep-05EUCTR2005-001895-11-ESBristol-Myers Squibb International Corporation1,200